Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Rolf Hartmann

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Rats

Genes & Molecular Sequences

Molecular Structure

Anatomy

Procedures

Preclinical Drug Evaluation

Occupations

Drug Design

Disorders

Prostatic Neoplasms

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
15
Müller-Vieira, Ursula
12
Marchais-Oberwinkler, Sandrine
12
Frotscher, Martin
11
Klein, Christian
11
Palusczak, Anja
9
Le Borgne, Marc
8
Le Baut, Guillaume
8
Palzer, Martina
8
Ehmer, Peter
8
Jose, Joachim
6
Haidar, Samer
6
Baston, Eckhard
6
Neugebauer, Alexander
6
Picard, Franck
6
Marchand, Pascal

Sign-in to see all Coauthors

Publications

TOP 3
Bey Emmanuel; Marchais-Oberwinkler Sandrine; Negri Matthias; Kruchten Patricia; Oster Alexander; Klein Tobias; Spadaro Alessandro; Werth Ruth; Frotscher Martin; Birk Barbara; Hartmann Rolf W
New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Ries Christina; Lucas Simon; Heim Ralf; Birk Barbara; Hartmann Rolf W
Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.
Stroba Adriana; Schaeffer Francis; Hindie Valerie; Lopez-Garcia Laura; Adrian Iris; Fröhner Wolfgang; Hartmann Rolf W; Biondi Ricardo M; Engel Matthias
3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Rolf Hartmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Bey Emmanuel; Marchais-Oberwinkler Sandrine; Negri Matthias; Kruchten Patricia; Oster Alexander; Klein Tobias; Spadaro Alessandro; Werth Ruth; Frotscher Martin; Birk Barbara; Hartmann Rolf W
New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Journal of medicinal chemistry 2009;52(21):6724-43.
2009: Ries Christina; Lucas Simon; Heim Ralf; Birk Barbara; Hartmann Rolf W
Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.
The Journal of steroid biochemistry and molecular biology 2009;116(3-5):121-6.
2009: Stroba Adriana; Schaeffer Francis; Hindie Valerie; Lopez-Garcia Laura; Adrian Iris; Fröhner Wolfgang; Hartmann Rolf W; Biondi Ricardo M; Engel Matthias
3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds.
Journal of medicinal chemistry 2009;52(15):4683-93.
2009: Ziegler Sigrid; Kronenberger Bernd; Albrecht Beatrice A-M; Kaul Artur; Gamer Anna-Lena; Klein Christian D; Hartmann Rolf W
Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2009;14(6):620-6.
2009: Hille Ulrike E; Hu Qingzhong; Vock Carsten; Negri Matthias; Bartels Marc; Müller-Vieira Ursula; Lauterbach Thomas; Hartmann Rolf W
Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
European journal of medicinal chemistry 2009;44(7):2765-75.
2009: Kruchten Patricia; Werth Ruth; Bey Emmanuel; Oster Alexander; Marchais-Oberwinkler Sandrine; Frotscher Martin; Hartmann Rolf W
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
The Journal of steroid biochemistry and molecular biology 2009;114(3-5):200-6.
2009: Kruchten Patricia; Werth Ruth; Marchais-Oberwinkler Sandrine; Frotscher Martin; Hartmann Rolf W
Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Molecular and cellular endocrinology 2009;301(1-2):154-7.
2009: Marchais-Oberwinkler Sandrine; Frotscher Martin; Ziegler Erika; Werth Ruth; Kruchten Patricia; Messinger Josef; Thole Hubert; Hartmann Rolf W
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Molecular and cellular endocrinology 2009;301(1-2):205-11.
2009: Al-Soud Yaseen A; Bey Emmanuel; Oster Alexander; Marchais-Oberwinkler Sandrine; Werth Ruth; Kruchten Patricia; Frotscher Martin; Hartmann Rolf W
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Molecular and cellular endocrinology 2009;301(1-2):212-5.
2008: Bey Emmanuel; Marchais-Oberwinkler Sandrine; Werth Ruth; Negri Matthias; Al-Soud Yaseen A; Kruchten Patricia; Oster Alexander; Frotscher Martin; Birk Barbara; Hartmann Rolf W
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Journal of medicinal chemistry 2008;51(21):6725-39.
2008: Lucas Simon; Heim Ralf; Negri Matthias; Antes Iris; Ries Christina; Schewe Katarzyna E; Bisi Alessandra; Gobbi Silvia; Hartmann Rolf W
Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Journal of medicinal chemistry 2008;51(19):6138-49.
2008: Pinto-Bazurco Mendieta Mariano A E; Negri Matthias; Hu Qingzhong; Hille Ulrike E; Jagusch Carsten; Jahn-Hoffmann Kerstin; Müller-Vieira Ursula; Schmidt Dirk; Lauterbach Thomas; Hartmann Rolf W
CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Archiv der Pharmazie 2008;341(10):597-609.
2008: Hu Qingzhong; Negri Matthias; Jahn-Hoffmann Kerstin; Zhuang Yan; Olgen Sureyya; Bartels Marc; Müller-Vieira Ursula; Lauterbach Thomas; Hartmann Rolf W
Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Bioorganic & medicinal chemistry 2008;16(16):7715-27.
2008: Pinto-Bazurco Mendieta Mariano A E; Negri Matthias; Jagusch Carsten; Müller-Vieira Ursula; Lauterbach Thomas; Hartmann Rolf W
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Journal of medicinal chemistry 2008;51(16):5009-18.
2008: Heim Ralf; Lucas Simon; Grombein Cornelia M; Ries Christina; Schewe Katarzyna E; Negri Matthias; Müller-Vieira Ursula; Birk Barbara; Hartmann Rolf W
Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
Journal of medicinal chemistry 2008;51(16):5064-74.
2008: Lézé Marie-Pierre; Palusczak Anja; Hartmann Rolf W; Le Borgne Marc
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(16):4713-5.
2008: Marchais-Oberwinkler Sandrine; Kruchten Patricia; Frotscher Martin; Ziegler Erika; Neugebauer Alexander; Bhoga Umadevi; Bey Emmanuel; Müller-Vieira Ursula; Messinger Josef; Thole Hubert; Hartmann Rolf W
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Journal of medicinal chemistry 2008;51(15):4685-98.
2008: Holzer Marcel; Ziegler Sigrid; Neugebauer Alexander; Kronenberger Bernd; Klein Christian D; Hartmann Rolf W
Structural modifications of salicylates: inhibitors of human CD81-receptor HCV-E2 interaction.
Archiv der Pharmazie 2008;341(8):478-84.
2008: Bey Emmanuel; Marchais-Oberwinkler Sandrine; Kruchten Patricia; Frotscher Martin; Werth Ruth; Oster Alexander; Algül Oztekin; Neugebauer Alexander; Hartmann Rolf W
Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bioorganic & medicinal chemistry 2008;16(12):6423-35.
2008: Frotscher Martin; Ziegler Erika; Marchais-Oberwinkler Sandrine; Kruchten Patricia; Neugebauer Alexander; Fetzer Ludivine; Scherer Christiane; Müller-Vieira Ursula; Messinger Josef; Thole Hubert; Hartmann Rolf W
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Journal of medicinal chemistry 2008;51(7):2158-69.
2008: Jagusch Carsten; Negri Matthias; Hille Ulrike E; Hu Qingzhong; Bartels Marc; Jahn-Hoffmann Kerstin; Pinto-Bazurco Mendieta Mariano A E; Rodenwaldt Barbara; Müller-Vieira Ursula; Schmidt Dirk; Lauterbach Thomas; Recanatini Maurizio; Cavalli Andrea; Hartmann Rolf W
Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.
Bioorganic & medicinal chemistry 2008;16(4):1992-2010.
2008: Pinto-Bazurco Mendieta Mariano A E; Negri Matthias; Jagusch Carsten; Hille Ulrike E; Müller-Vieira Ursula; Schmidt Dirk; Hansen Klaus; Hartmann Rolf W
Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.
Bioorganic & medicinal chemistry letters 2008;18(1):267-73.
2008: Holzer Marcel; Ziegler Sigrid; Kronenberger Bernd; Klein Christian D; Hartmann Rolf W
Microwave-Assisted Syntheses of Amino Acid Ester Substituted Benzoic Acid Amides: Potential Inhibitors of Human CD81-Receptor HCV-E2 Interaction.
The open medicinal chemistry journal 2008;2():21-5.
2008: Holzer Marcel; Ziegler Sigrid; Albrecht Beatrice; Kronenberger Bernd; Kaul Artur; Bartenschlager Ralf; Kattner Lars; Klein Christian D; Hartmann Rolf W
Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization.
Molecules (Basel, Switzerland) 2008;13(5):1081-110.
2007: Le Borgne Marc; Marchand Pascal; Nourrisson Marie-Renee; Loquet Denis; Palzer Martina; Le Baut Guillaume; Hartmann Rolf W
Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2007;22(5):667-76.
2007: Neugebauer Alexander; Hartmann Rolf W; Klein Christian D
Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods.
Journal of medicinal chemistry 2007;50(19):4665-8.
2007: Gobbi Silvia; Cavalli Andrea; Negri Matthias; Schewe Katarzyna E; Belluti Federica; Piazzi Lorna; Hartmann Rolf W; Recanatini Maurizio; Bisi Alessandra
Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.
Journal of medicinal chemistry 2007;50(15):3420-2.
2007: Schertl Sabine; Hartmann Rolf W; Batzl-Hartmann Christine; Spruss Thilo; Maucher Anton; von Angerer Erwin; Schiller Claus D; Schneider Martin R; Gust Ronald; Schönenberger Helmut
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
Journal of cancer research and clinical oncology 2007;133(3):153-67.
2006: Engel Matthias; Hindie Valerie; Lopez-Garcia Laura A; Stroba Adriana; Schaeffer Francis; Adrian Iris; Imig Jochen; Idrissova Leila; Nastainczyk Wolfgang; Zeuzem Stefan; Alzari Pedro M; Hartmann Rolf W; Piiper Albrecht; Biondi Ricardo M
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds.
The EMBO journal 2006;25(23):5469-80.
2006: Dragan Calin-Aurel; Hartmann Rolf W; Bureik Matthias
A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
Journal of enzyme inhibition and medicinal chemistry 2006;21(5):547-56.
2006: Görlitzer K; Bonnekessel Ch; Jones P G; Palusczak A; Hartmann R W
[Derivatives of exemestane--synthesis and evaluation of aromatase inhibition]
Die Pharmazie 2006;61(7):575-81.
2006: Gobbi Silvia; Cavalli Andrea; Rampa Angela; Belluti Federica; Piazzi Lorna; Paluszcak Anja; Hartmann Rolf W; Recanatini Maurizio; Bisi Alessandra
Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
Journal of medicinal chemistry 2006;49(15):4777-80.
2006: Schuster Daniela; Laggner Christian; Steindl Theodora M; Palusczak Anja; Hartmann Rolf W; Langer Thierry
Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors.
Journal of chemical information and modeling 2006;46(3):1301-11.
2006: Voets Marieke; Antes Iris; Scherer Christiane; Müller-Vieira Ursula; Biemel Klaus; Marchais-Oberwinkler Sandrine; Hartmann Rolf W
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Journal of medicinal chemistry 2006;49(7):2222-31.
2006: Lézé Marie-Pierre; Le Borgne Marc; Pinson Patricia; Palusczak Anja; Duflos Muriel; Le Baut Guillaume; Hartmann Rolf W
Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.
Bioorganic & medicinal chemistry letters 2006;16(5):1134-7.
2006: Salem Ola I A; Frotscher Martin; Scherer Christiane; Neugebauer Alexander; Biemel Klaus; Streiber Martina; Maas Ruth; Hartmann Rolf W
Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids.
Journal of medicinal chemistry 2006;49(2):748-59.
2006: Ulmschneider Sarah; Negri Matthias; Voets Marieke; Hartmann Rolf W
Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Bioorganic & medicinal chemistry letters 2006;16(1):25-30.
2005: Loge Cedric; Le Borgne Marc; Marchand Pascal; Robert Jean-Michel; Le Baut Guillaume; Palzer Martina; Hartmann Rolf W
Three-dimensional model of cytochrome P450 human aromatase.
Journal of enzyme inhibition and medicinal chemistry 2005;20(6):581-5.
2005: Cavalli Andrea; Bisi Alessandra; Bertucci Carlo; Rosini Carlo; Paluszcak Anja; Gobbi Silvia; Giorgio Egidio; Rampa Angela; Belluti Federica; Piazzi Lorna; Valenti Piero; Hartmann Rolf W; Recanatini Maurizio
Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach.
Journal of medicinal chemistry 2005;48(23):7282-9.
2005: Voets Marieke; Antes Iris; Scherer Christiane; Müller-Vieira Ursula; Biemel Klaus; Barassin Catherine; Marchais-Oberwinkler Sandrine; Hartmann Rolf W
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Journal of medicinal chemistry 2005;48(21):6632-42.
2005: Müller-Vieira Ursula; Angotti Marc; Hartmann Rolf W
The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
The Journal of steroid biochemistry and molecular biology 2005;96(3-4):259-70.
2005: Angotti Marc; Hartmann Rolf W; Kirby Andrew J; Simons Claire; Nicholls Paul J; Sewell Robert D E; Smith H John
Effect of 2-(4-aminophenylmethyl)-6-hydroxy-3, 4-dihydronaphthalen-1(2H)-one on all-trans and 13-cis-retinoic acid levels in plasma quantified by high perfomance liquid chromatography coupled to tandem mass spectrometry.
Journal of enzyme inhibition and medicinal chemistry 2005;20(3):219-26.
2005: Jindal Dharam Paul; Bedi Vikas; Jit Birinder; Karkra Nalin; Guleria Sheetal; Bansal Ranju; Palusczak Anja; Hartmann Rolf W
Synthesis and study of some new N-substituted imide derivatives as potential anticancer agents.
Farmaco (Società chimica italiana : 1989) 2005;60(4):283-90.
2005: Ulmschneider Sarah; Müller-Vieira Ursula; Mitrenga Markus; Hartmann Rolf W; Oberwinkler-Marchais Sandrine; Klein Christian D; Bureik Matthias; Bernhardt Rita; Antes Iris; Lengauer Thomas
Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Journal of medicinal chemistry 2005;48(6):1796-805.
2005: Ulmschneider Sarah; Müller-Vieira Ursula; Klein Christian D; Antes Iris; Lengauer Thomas; Hartmann Rolf W
Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Journal of medicinal chemistry 2005;48(5):1563-75.
2005: Streiber Martina; Picard Franck; Scherer Christiane; Seidel Stefanie B; Hartmann Rolf W
Methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5 alpha-reductase type 1 and type 2.
Journal of pharmaceutical sciences 2005;94(3):473-80.
2005: Panter Baerbel U; Jose Joachim; Hartmann Rolf W
5alpha-reductase in human embryonic kidney cell line HEK293: evidence for type II enzyme expression and activity.
Molecular and cellular biochemistry 2005;270(1-2):201-8.
2005: Mathur Sonal; Park Jung Dae; Kim Dong H; Hartmann Rolf W
A method for screening enzyme inhibitors using size exclusion chromatography and ESI-LC-MS/MS.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2005;10(1):30-5.
2004: Lézé Marie-Pierre; Le Borgne Marc; Marchand Pascal; Loquet Denis; Kogler Manuela; Le Baut Guillaume; Palusczak Anja; Hartmann Rolf W
2- and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2004;19(6):549-57.
2004: Leonetti Francesco; Favia Angelo; Rao Angela; Aliano Rosaria; Paluszcak Anja; Hartmann Rolf W; Carotti Angelo
Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.
Journal of medicinal chemistry 2004;47(27):6792-803.
2004: Bild Thomas; Jose Joachim; Hartmann Rolf W
Discovery of inhibitors of MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action.
Archiv der Pharmazie 2004;337(12):687-94.
2004: Mathur Sonal; Picard Franck; Dossou Ulrich; Barassin Catherine; Seidel Stefanie B; Kang Min-Jung; Hartmann Rolf W
Evaluation of cell permeation of a potent 5alpha-reductase inhibitor using MALDI-TOF MS.
Journal of enzyme inhibition and medicinal chemistry 2004;19(5):425-9.
2004: Kang Min-Jung; Mathur Sonal; Hartmann Rolf W
Quantitative analysis of 5 alpha-reductase inhibitors in DU145 cells using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(7):762-9.
2004: Voets Marieke; Müller-Vieira Ursula; Marchais-Oberwinkler Sandrine; Hartmann Rolf W
Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids.
Archiv der Pharmazie 2004;337(7):411-6.
2004: Gupta Ranju; Jindal Dharam Paul; Jit Birinder; Narang Gaurav; Palusczak Anja; Hartmann Rolf W
Synthesis and evaluation of a dimer of 2-(4-pyridylmethyl)-1-indanone as a novel nonsteroidal aromatase inhibitor.
Archiv der Pharmazie 2004;337(7):398-401.
2004: Schertl Sabine; Hartmann Rolf W; Batzl-Hartmann Christine; Bernhardt Günther; Spruss Thilo; Beckenlehner Karin; Koch Marion; Krauser Rudolf; Schlemmer Richard; Gust Ronald; Schönenberger Helmut
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Archiv der Pharmazie 2004;337(6):349-59.
2004: Schertl Sabine; Hartmann Rolf W; Batzl-Hartmann Christine; Bernhardt Günther; Spruss Thilo; Beckenlehner Karin; Koch Marion; Krauser Rudolf; Schlemmer Richard; Gust Ronald; Schönenberger Helmut
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Archiv der Pharmazie 2004;337(6):335-48.
2004: Lisurek Michael; Kang Min-Jung; Hartmann Rolf W; Bernhardt Rita
Identification of monohydroxy progesterones produced by CYP106A2 using comparative HPLC and electrospray ionisation collision-induced dissociation mass spectrometry.
Biochemical and biophysical research communications 2004;319(2):677-82.
2004: Hartmann Rolf W; Palusczak Anja; Lacan Fabrice; Ricci Giacomo; Ruzziconi Renzo
CYP 17 and CYP 19 inhibitors. Evaluation of fluorine effects on the inhibiting activity of regioselectively fluorinated 1-(Naphthalen-2-ylmethyl)imidazoles.
Journal of enzyme inhibition and medicinal chemistry 2004;19(2):145-55.
2004: Aboul-Enein Hassan Y; Kladna Alexandra; Kruk Irena; Lichszteld Krzysztof; Marchlewicz Mariola; Michalska Teresa; Salem Ola I A; Hartmann Rolf W
Prooxidant and antioxidant action of 4-(4-phenoxybenzoyl)benzoic acid derivatives.
Biopolymers 2004;73(5):631-9.
2004: Neugebauer Alexander; Klein Christian D P; Hartmann Rolf W
Protein-dynamics of the putative HCV receptor CD81 large extracellular loop.
Bioorganic & medicinal chemistry letters 2004;14(7):1765-9.
2004: Hutschenreuter Tilman U; Ehmer Peter B; Hartmann Rolf W
Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme.
Journal of enzyme inhibition and medicinal chemistry 2004;19(1):17-32.
2004: Kang Min-Jung; Lisurek Michael; Bernhardt Rita; Hartmann Rolf W
Use of high-performance liquid chromatography/electrospray ionization collision-induced dissociation mass spectrometry for structural identification of monohydroxylated progesterones.
Rapid communications in mass spectrometry : RCM 2004;18(23):2795-800.
2003: Marchand Pascal; Le Borgne Marc; Palzer Martina; Le Baut Guillaume; Hartmann Rolf W
Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.
Bioorganic & medicinal chemistry letters 2003;13(9):1553-5.
2003: Haidar Samer; Ehmer Peter B; Barassin Stephan; Batzl-Hartmann Christine; Hartmann Rolf W
Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
The Journal of steroid biochemistry and molecular biology 2003;84(5):555-62.
2003: Hartmann Rolf W; Müller Ursula; Ehmer Peter B
Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis.
European journal of medicinal chemistry 2003;38(4):363-6.
2003: Baston Eckhard; Salem Ola I A; Hartmann Rolf W
Cyclohex-1-ene carboxylic acids: synthesis and biological evaluation of novel inhibitors of human 5 alpha reductase.
Archiv der Pharmazie 2003;336(1):31-8.
2002: Baston Eckhard; Salem Ola I A; Hartmann Rolf W
6-Substituted 3,4-dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5alpha reductase inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2002;17(5):303-20.
2002: Picard Franck; Barassin Stephan; Mokhtarian Armand; Hartmann Rolf W
Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
Journal of medicinal chemistry 2002;45(16):3406-17.
2002: Picard Franck; Hartmann Rolf W
N-substituted 4-(4-carboxyphenoxy)benzamides. Synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2.
Journal of enzyme inhibition and medicinal chemistry 2002;17(3):187-96.
2002: Ehmer Peter B; Bureik Matthias; Bernhardt Rita; Müller Ursula; Hartmann Rolf W
Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.
The Journal of steroid biochemistry and molecular biology 2002;81(2):173-9.
2002: Hartmann Rolf W; Ehmer Peter B; Haidar Samer; Hector Markus; Jose Joachim; Klein Christian D P; Seidel Stefanie B; Sergejew Tom F; Wachall Bertil G; Wächter Gerald A; Zhuang Yan
Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
Archiv der Pharmazie 2002;335(4):119-28.
2002: Salem Ola I A; Schulz Tobias; Hartmann Rolf W
Synthesis and biological evaluation of 4-(4-(alkyl- and phenylaminocarbonyl)benzoyl)benzoic acid derivatives as non-steroidal inhibitors of steroid 5 alpha-reductase isozymes 1 and 2.
Archiv der Pharmazie 2002;335(2-3):83-8.
2002: Picard Franck; Schulz Tobias; Hartmann Rolf W
5-Phenyl substituted 1-methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2.
Bioorganic & medicinal chemistry 2002;10(2):437-48.
2002: Haidar Samer; Hartmann Rolf W
C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation.
Archiv der Pharmazie 2002;335(11-12):526-34.
2001: Haidar S; Ehmer P B; Hartmann R W
Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).
Archiv der Pharmazie 2001;334(12):373-4.
2001: Kleber A; Hartmann R W; Jose J
No effect of thromboxane A2 on the attachment of tumor cell lines MDA MB 231, DU145, and U937 to the basement membrane in an in-vitro model.
Journal of cancer research and clinical oncology 2001;127(12):751-4.
2001: Reichert W; Michel A; Hartmann R W; Jose J
Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification.
The Journal of steroid biochemistry and molecular biology 2001;78(3):275-84.
2001: Haidar S; Klein C D; Hartmann R W
Synthesis and evaluation of steroidal hydroxamic acids as inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).
Archiv der Pharmazie 2001;334(4):138-40.
2001: Schertl S; Hartmann R W; Batzl-Hartmann C; Schlemmer R; Spruss T; Bernhardt G; Gust R; Schönenberger H
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
Archiv der Pharmazie 2001;334(4):125-37.
2001: Recanatini M; Bisi A; Cavalli A; Belluti F; Gobbi S; Rampa A; Valenti P; Palzer M; Palusczak A; Hartmann R W
A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
Journal of medicinal chemistry 2001;44(5):672-80.
2001: Baston E; Klein C D; Grimminger W; Hebecker N; Hartmann R W
Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type.
Anti-cancer drug design 2001;16(1):37-47.
2001: Reichert W; Hartmann R W; Jose J
Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors.
Journal of enzyme inhibition 2001;16(1):47-53.
2000: Ehmer P B; Jose J; Hartmann R W
Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli.
The Journal of steroid biochemistry and molecular biology 2000;75(1):57-63.
2000: Hartmann R W; Hector M; Wachall B G; Palusczak A; Palzer M; Huch V; Veith M
Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17).
Journal of medicinal chemistry 2000;43(23):4437-45.
2000: Hartmann R W; Hector M; Haidar S; Ehmer P B; Reichert W; Jose J
Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
Journal of medicinal chemistry 2000;43(22):4266-77.
2000: Baston E; Palusczak A; Hartmann R W
6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2.
European journal of medicinal chemistry 2000;35(10):931-40.
2000: Le Borgne M; Duflos M; Le Baut G; Nicholls P J; Hartmann R W
[Synthesis and biological evaluation of indole derivatives acting as anti-inflammatory or antitumoral drugs]
Annales pharmaceutiques françaises 2000;58(5):316-20.
2000: Reichert W; Jose J; Hartmann R W
5 alpha-reductase in intact DU145 cells: evidence for isozyme I and evaluation of novel inhibitors.
Archiv der Pharmazie 2000;333(7):201-4.
2000: Picard F; Baston E; Reichert W; Hartmann R W
Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2.
Bioorganic & medicinal chemistry 2000;8(6):1479-87.
2000: Zhuang Y; Wachall B G; Hartmann R W
Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase-C17, 20-lyase (P450 17).
Bioorganic & medicinal chemistry 2000;8(6):1245-52.
2000: Hartmann R W; Reichert M
New nonsteroidal steroid 5 alpha-reductase inhibitors. Syntheses and structure-activity studies on carboxamide phenylalkyl-substituted pyridones and piperidones.
Archiv der Pharmazie 2000;333(5):145-53.
2000: Jacobs C; Frotscher M; Dannhardt G; Hartmann R W
1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.
Journal of medicinal chemistry 2000;43(9):1841-51.
1999: Hartmann R W; Frotscher M
1-Imidazolylcarbonyloxy-substituted tetrahydroquinolines and pyridines: synthesis and evaluation of P450 TxA2 inhibition.
Archiv der Pharmazie 1999;332(10):358-62.
1999: Wachall B G; Hector M; Zhuang Y; Hartmann R W
Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
Bioorganic & medicinal chemistry 1999;7(9):1913-24.
1999: Baston E; Hartmann R W
N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity.
Bioorganic & medicinal chemistry letters 1999;9(11):1601-6.
1999: Le Borgne M; Marchand P; Delevoye-Seiller B; Robert J M; Le Baut G; Hartmann R W; Palzer M
New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles.
Bioorganic & medicinal chemistry letters 1999;9(3):333-6.
1998: Zhuang Y; Hartmann R W
Synthesis of novel oximes of 2-aryl-6-methoxy-3,4-dihydronaphthalene and their evaluation as inhibitors of 17 alpha-hydroxylase-C17,20-lyase (P450 17).
Archiv der Pharmazie 1998;331(1):36-40.
1997: Zhuang Y; Zapp J; Hartmann R W
Synthesis of Z- and E-1-methyl-2-(1-hydroximinoethyl)-6-methoxy-3,4-dihydronaphthalene and evaluation as inhibitors of 17 alpha-hydroxylase-C17,20-lyase (P450 17).
Archiv der Pharmazie 1997;330(11):359-61.
1997: Le Borgne M; Marchand P; Duflos M; Delevoye-Seiller B; Piessard-Robert S; Le Baut G; Hartmann R W; Palzer M
Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom.
Archiv der Pharmazie 1997;330(5):141-5.
1996: Njar V C; Hector M; Hartmann R W
20-amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase/C17,20-lyase (P450 17).
Bioorganic & medicinal chemistry 1996;4(9):1447-53.
1996: Sergejew T F; Hartmann R W
Effect of a diphenylethylenediamine platinum complex on steroidogenesis in rats.
The Journal of steroid biochemistry and molecular biology 1996;58(2):243-8.
1996: Hartmann R W; Frotscher M; Ledergerber D; Wächter G A; Grün G L; Sergejew T F
Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2.
Archiv der Pharmazie 1996;329(5):251-61.
1996: Njar V C; Düerkop J; Hartmann R W
Synthesis of 10 beta-(1'-azirinyl)estr-4-en-3,17-dione as an aromatase inhibitor.
Steroids 1996;61(3):138-43.
1996: Wächter G A; Hartmann R W; Sergejew T; Grün G L; Ledergerber D
Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17.
Journal of medicinal chemistry 1996;39(4):834-41.
1996: Njar V C; Düerkop J; Hartmann R W
Novel 19-(cyclopropylamino)-androst-4-en-3,17-dione: a mechanism-based inhibitor of aromatase.
Journal of enzyme inhibition 1996;10(1):47-56.
1995: Hartmann R W; Wächter G A; Sergejew T; Würtz R; Düerkop J
4,5-Dihydro-3-(2-pyrazinyl)naphtho[1,2-c]pyrazole: a potent and selective inhibitor of steroid-17 alpha-hydroxylase-C17,20-lyase (P450 17).
Archiv der Pharmazie 1995;328(7-8):573-5.
1995: Hartmann R W; Bayer H; Grün G; Sergejew T; Bartz U; Mitrenga M
Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom.
Journal of medicinal chemistry 1995;38(12):2103-11.
1995: Kattner L; Göhring S; Hartmann R W
Synthesis and biochemical evaluation of (carbamoylalkenyl)phenyloxy carboxylic acid derivatives as non-steroidal 5 alpha-reductase inhibitors.
Archiv der Pharmazie 1995;328(3):239-45.
1995: Njar V C; Grün G; Hartmann R W
Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom).
Journal of enzyme inhibition 1995;9(3):195-202.
1995: Ledergerber D; Hartmann R W
Development of a screening assay for the in vitro evaluation of thromboxane A2 synthase inhibitors.
Journal of enzyme inhibition 1995;9(4):253-61.
1994: Hartmann R W; Bayer H; Grün G
Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins.
Journal of medicinal chemistry 1994;37(9):1275-81.
1994: Sergejew T; Hartmann R W
Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Journal of enzyme inhibition 1994;8(2):113-22.
1992: Hartmann R W; Grün G; Bartz U; Palzer M
Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type.
The Journal of steroid biochemistry and molecular biology 1992;43(7):641-8.
1992: Hartmann R W; Batzl C; Pongratz T M; Mannschreck A
Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4-aminophenyl)piperidine-2,6-diones.
Journal of medicinal chemistry 1992;35(12):2210-4.
1991: Bayer H; Hartmann R W
[New inhibitors of aromatase: synthesis and biological activity of pyridyl-substituted phenanthrenone derivatives]
Archiv der Pharmazie 1991;324(11):833-6.
1991: Bayer H; Hartmann R W
[Pyridyl-substituted tetralone derivatives: a new class of nonsteroidal aromatase inhibitors]
Archiv der Pharmazie 1991;324(10):815-20.
1991: Bayer H; Batzl C; Hartmann R W; Mannschreck A
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
Journal of medicinal chemistry 1991;34(9):2685-91.
1987: Batzl C; Hartmann R W
[Inhibitors of aromatase. Synthesis and pharmacologic action of potential mammary tumor-inhibiting 4-alkyl-3-(4-aminophenyl)-3-ethylpiperidine-2,6-diones]
Archiv der Pharmazie 1987;320(1):51-8.
1986: Hartmann R W; Batzl C
Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones.
Journal of medicinal chemistry 1986;29(8):1362-9.

Sign-in to see more